ArticleNature communications2022
Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 88 citations in OpenAlex.
- Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial.Signal transduction and targeted therapy · 2025Trial
- Canonical and noncanonical autophagy in immunity.Immunity · 2026Review
- Autophagy modulation in cancer.Nature reviews. Drug discovery · 2026Review
- Sortilin is Associated with PGRN-Mediated Endoplasmic Reticulum Stress and Activation of Microglia in a Rat Model of Degenerative Cervical Myelopathy.Neuromolecular medicine · 2026Article
- Messing with Signal 1: How Perturbed MHC Class I Antigen Presentation Contributes to Cancer.Cells · 2026Review
- The Aging Microenvironment Is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer.Cancer research · 2026Article
- Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma.Nature communications · 2026Article
- Progranulin promotes glioma progression via interaction with cathepsin D and serves as a diagnostic and prognostic biomarker.Discover oncology · 2026Article
- Autophagy Modulates Immunogenic Cell Death in Cancer.Cancers · 2026Review
- Article
- Single-cell multiome and spatial profiling reveals pancreas cell type-specific gene regulatory programs of type 1 diabetes progression.Science advances · 2025Article
- Natural vaccine adjuvants from traditional Chinese medicines: Mechanisms to applications.Acta pharmaceutica Sinica. B · 2025Review
- Review
- Decoding MHC loss: Molecular mechanisms and implications for immune resistance in cancer.Clinical and translational medicine · 2025Review
- Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma.Expert opinion on therapeutic targets · 2025Review
- B4GALT5 inhibits CD8Journal for immunotherapy of cancer · 2025Article
- Autophagy in tumor immune escape and immunotherapy.Molecular cancer · 2025Review
- PCBP2 promotes immune evasion via cGAS-STING pathway in biochemical recurrence of prostate cancer.APL bioengineering · 2025Article
- The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer.Journal of advanced research · 2025Review
- A novel immune-related gene prognostic signature combining immune cell infiltration and immune checkpoint for glioblastoma patients.Translational cancer research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 10 institutions in 6 countries.
Phyllis F CheungBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
JiaJin YangBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Rui FangBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Arianna BorgersBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Kirsten KrengelBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Anne StoffelBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Kristina AlthoffBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Chi Wai YipDepartment of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0000-0003-3327-5695
Elaine H L SiuDepartment of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Linda W C NgDepartment of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Karl S LangInstitute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Lamin B ChamInstitute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Daniel R EngelDepartment of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany.
Camille SounDepartment of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany.
Igor CimaDKFZ-Division Translational Neurooncology at the WTZ, German Cancer Consortium (DKTK partner site Essen/Düsseldorf), Essen, Germany.ORCID http://orcid.org/0000-0002-6196-6971
Björn SchefflerDKFZ-Division Translational Neurooncology at the WTZ, German Cancer Consortium (DKTK partner site Essen/Düsseldorf), Essen, Germany.
Jana K StrieflerUniversitätsmedizin Charité Berlin, CONKO Study Group, Department of Medical Oncology, Haematology and Tumorimmunology, Berlin, Germany.
Marianne SinnUniversitätsmedizin Charité Berlin, CONKO Study Group, Department of Medical Oncology, Haematology and Tumorimmunology, Berlin, Germany.
Marcus BahraDepartment of Surgical Oncology and Robotics, Krankenhaus Waldfriede, Berlin, Germany.
Uwe PelzerMedical Department, Division of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Berlin, Germany.ORCID http://orcid.org/0000-0001-9213-2737
Helmut OettlePraxis und Tagesklinik, Dresden, Germany.
Peter MarkusDepartment of General, Visceral and Trauma Surgery, Elisabeth Hospital Essen, Essen, Germany.
Esther M M SmeetsDepartment of Medical Imaging, Radboud university medical Center, Nijmegen, The Netherlands.
Erik H J G AarntzenDepartment of Medical Imaging, Radboud university medical Center, Nijmegen, The Netherlands.
Konstantinos SavvatakisBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Sven-Thorsten LiffersBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Smiths S LueongBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Christian NeanderBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Anna BazarnaBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Xin ZhangBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Annette PaschenDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Howard C CrawfordRogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Anthony W H ChanDepartment of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Siu Tim CheungDepartment of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. stcheung@surgery.cuhk.edu.hk.ORCID http://orcid.org/0000-0003-2147-315X
Jens T SivekeBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany. j.siveke@dkfz.de.ORCID http://orcid.org/0000-0002-8772-4778
German Cancer Research Center · DEChinese University of Hong Kong · HKCharité - Universitätsmedizin Berlin · DEUniversity of Duisburg-Essen · DEDeutschen Konsortium für Translationale Krebsforschung · DEEssen University Hospital · DERadboud University Nijmegen · NLElisabeth-Krankenhaus Essen · DEKrankenhaus Waldfriede · DEUniversity of Michigan · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune evasion is indispensable for cancer initiation and progression, although its underlying mechanisms in pancreatic ductal adenocarcinoma (PDAC) are not fully known. Here, we characterize the function of tumor-derived PGRN in promoting immune evasion in primary PDAC. Tumor- but not macrophage-derived PGRN is associated with poor overall survival in PDAC. Multiplex immunohistochemistry shows low MHC class I (MHCI) expression and lack of CD8
Indexed as
AdenocarcinomaAnimalsAntibodies, NeutralizingAntigens, ViralAutophagyCarcinoma, Pancreatic DuctalCD8-Positive T-LymphocytesCell Line, TumorCell MovementCohort StudiesCytotoxicity, ImmunologicGene ExpressionGlycoproteinsHistocompatibility Antigens Class IHumansLymphocytic choriomeningitis virusAntibodies, NeutralizingAntigens, Viralglycoprotein peptide 33-41, Lymphocytic choriomeningitis virusGlycoproteinsGRN protein, humanHistocompatibility Antigens Class IPeptide FragmentsProgranulinsViral Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.